Madrigal Pharmaceuticals, Inc.
NMS: MDGLLive Quote
About Madrigal Pharmaceuticals, Inc.
Healthcare
Biotechnology
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
📊 Fundamental Analysis
Madrigal Pharmaceuticals, Inc. demonstrates a profit margin of -30.1%, which is below the sector average, suggesting competitive pressure.
The company recently reported 210.8% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -42.5%, which indicates that capital utilization is currently under pressure.
At a current price of $519.61, MDGL currently sits at the 73rd percentile of its 52-week range (Range: $265.00 - $615.00).
🏥 Financial Health
🔴
Profit Margin
Weak
⚠️
Debt/Equity
Moderate
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$11.00B
Trailing P/E
--
Forward P/E
40.61
Beta (5Y)
-1.01
52W High
$615.00
52W Low
$265.00
Avg Volume
365K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App